According to experts in this field, fragment-based drug discovery solutions have facilitated the identification of viable pharmacological leads against otherwise hard to target biomolecules. In fact, many service provider companies are offering fragment libraries and support to the medical research community in order to develop an appropriate intervention to treat the illness caused by the SARS-CoV-2 virus.

To order this 170+ page report, which features 55+ figures and 80+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

The USD 1.6 billion (by 2030) financial opportunity within the fragment-based drug discovery market has been analyzed across the following segments:
 Type of Screening Technique Used
 X-ray Crystallography
 Nuclear Magnetic Resonance
 Surface Plasmon Resonance
 Other Screening Techniques

 Type of Service Offered
 Library Screening
 Fragment Screening
 Fragment Optimization

 End User
 Industry Players
 Non-Industry Players

 Key geographical regions
 North America (US and Canada)
 Europe (UK, France, Germany, Spain, Italy, and rest of Europe)
 Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world)

The “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030 report features the following companies, which we identified to be key players in this domain:
 2bind
 Charles River Laboratories
 ChemAxon
 ComInnex
 Creative Biolabs
 Creative Biostructure
 CRELUX
 Domainex
 Evotec
 Red Glead Discovery
 SARomics Biostructures
 Shanghai ChemPartner
 Sygnature Discovery
 Vernalis Research

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
According to experts in this field, fragment-based drug discovery solutions have facilitated the identification of viable pharmacological leads against otherwise hard to target biomolecules. In fact, many service provider companies are offering fragment libraries and support to the medical research community in order to develop an appropriate intervention to treat the illness caused by the SARS-CoV-2 virus. To order this 170+ page report, which features 55+ figures and 80+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html The USD 1.6 billion (by 2030) financial opportunity within the fragment-based drug discovery market has been analyzed across the following segments:  Type of Screening Technique Used  X-ray Crystallography  Nuclear Magnetic Resonance  Surface Plasmon Resonance  Other Screening Techniques  Type of Service Offered  Library Screening  Fragment Screening  Fragment Optimization  End User  Industry Players  Non-Industry Players  Key geographical regions  North America (US and Canada)  Europe (UK, France, Germany, Spain, Italy, and rest of Europe)  Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world) The “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030 report features the following companies, which we identified to be key players in this domain:  2bind  Charles River Laboratories  ChemAxon  ComInnex  Creative Biolabs  Creative Biostructure  CRELUX  Domainex  Evotec  Red Glead Discovery  SARomics Biostructures  Shanghai ChemPartner  Sygnature Discovery  Vernalis Research To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html Contact Details Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
WWW.ROOTSANALYSIS.COM
Fragment-based Drug Discovery Market: Library and Service Providers | Industry Analysis | Market Size | 2030
Market research report on fragment based drug discovery with a focus on opportunities for library and service providers
0 Comments 0 Shares
Sponsored